Multiple Myeloma
The Transplant Sessions: ASH 2020 highlights
The management of post-transplantation relapse and immune attack is an ongoing battle in patients undergoing bone marrow transplants. The efficacy…
Date: 23rd April 2021
The Myeloma Sessions: Post-ASH 2020 UK Discussion
The development of immunomodulatory agents and proteasome inhibitors alongside stem cell transplantation and chemotherapy has significantly improved the treatment options…
Date: 19th April 2021
The Myeloma Sessions: key updates from ASH 2020
Over the last decades, a deeper understanding of multiple myeloma’s complex pathobiology has transformed the diagnosis, prognosis, and treatment paradigm,…
Date: 22nd February 2021
Myeloma at ASH 2020: talquetemab, CARTITUDE-1 & highlights
The field of multiple myeloma is rapidly evolving and can be credited to an increased understanding of the biology of…
Date: 20th January 2021
Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial updates and gene-edited effector cells
Cell therapy involves the transplantation of viable cells into a patient in order to trigger a medicinal effect. CAR-T is…
Date: 1st October 2020
SOHO 2020: Next questions in hematological malignancies
The Society of Hematologic Oncology (SOHO) 2020 Virtual Annual Meeting brought together global leading experts in hematological oncology who updated…
Date: 25th September 2020
The Myeloma Sessions: Evolving management of myeloma & COVID-19
Patients with cancer frequently exhibit poorer post-COVID-19 infection outcomes, therefore the management of patients with hematological malignancies remains of high…
Date: 6th August 2020
The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation
The ongoing COVID-19 pandemic caused by SARS-CoV-2 is an international public health issue and patients with cancer consistently demonstrate poorer…
Date: 28th July 2020
The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients
The multiple myeloma field is rapidly evolving, with exciting developments in strategies for the treatment of smoldering myeloma, relapsed/refractory (R/R)…
Date: 3rd July 2020
Myeloma management in the COVID-19 era
The management of multiple myeloma presents many clinical challenges. The additional layer of complication COVID-19 places on patients and clinicians…
Date: 14th April 2020
CAR T-cell therapy & multiple myeloma: past, present & future
CAR-T cell therapy offers a potentially paradigm-changing new treatment for multiple myeloma. Additionally, CAR-T toxicity is may be more manageable…
Date: 2nd April 2020
Induction therapy in myeloma: an ever-changing paradigm
In the majority of hematologic malignancies, induction treatment is given to achieve complete remission. In multiple myeloma, this has only…
Date: 18th July 2019